DRUGS USED IN MOOD DISORDERS

Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK), MRCPE, DMT(UK) (2013/04/02)

LEARNING OUTCOMES

By the end of the lecture, students will be able to describe the following with regard to mood stabilizers

- Mechanisms of action
- Pharmacokinetics
- Adverse and toxic effects

OUTLINE....

- A. Definition-Bipolar Affective Disorder
- B. Classification of Mood Stabilizers
- c. Pharmacological Profile of Lithium
- D. Toxicity of Lithium

BIPOLAR AFFECTIVE DISORDER

 Recurrent episodes of elevated mood and depression, together with changes in activity levels



MANIC SYMPTOMS

- Elevated or irritable mood
- Increased activity or psychomotor agitation
- Reduced need for sleep
- Inflated self esteem or grandiosity
- Increased or pressure of speech
- Flight of ideas

TREATMENT OF BPD

- Acute treatment of episodes of illness aims to resolve symptoms and reduce immediate risk to self or others
- Long term treatment aims to prevent future episodes of illness and help regain a premorbid level of functioning and reduce longer term suicide risk

MOOD STABILISERS

A. Lithium

B. Anticonvulsants

- i. Sodium valproate
- ii. Carbamazepine
- iii. Lamotrigine

c. Antipsychotics

i. Quetiapine

LITHIUM

- Lithium carbonate and lithium citrate used therapeutically
- Mechanism of action poorly understood
- Several hypotheses:
 - I. impact on monoamines
 - II. affect secondary messengers

PHARMACOKINETICS


- Absorbed readily and almost completely from the GI tract; peak concentrations in 1-2 hrs
- Distributes to a volume of distribution ~TBW
- Elimination
 - 95%- in urine
 - 4-5% in sweat
 - 1% in faeces

RENAL ELIMINATION

- Two phases:
 - initial phase first 6-12 hrs
 - slow phase- over the next 10-14 days
- Elimination $t_{1/2} \sim 20-24$ hours
- Completely filtered, and 80% is reabsorbed in the proximal tubules
- Li⁺ competes with Na⁺ for reabsorption, and Li⁺ retention increased by Na⁺ loss
 e.g. Diarrhoea, thiazide diuretics

SERUM LEVEL MONITORING

- Serum concentrations of Li⁺ follow a clear doseeffect relationship between 0.4 and 1.0 mEq/L
- But with a corresponding dose-dependent rise in polyuria and tremor as well i.e. Narrow therapeutic index
- .: Serum level monitoring crucial
- Therapeutic Li concentration : 0.6 1.0 mmol/L



Drug dose

- GI Effects:
 - Anorexia
 - Nausea, vomiting
 - Abdominal pain
 - Diarrhoea

- CNS Effects
 - Fine hand tremor
 - Incoordination, ataxia, or slurred speech
 - Seizures
 - Weight gain
- Renal Effects
 - Nephrogenic diabetes insipidus polyuria and compensatory polydipsia

Endocrine Effects

- Goitre and hypothyroidism commonly
 - (Due to competition for the iodide transport within the thyroid and inhibition of synthesis and release of thyroid hormones)
- Rarely thyrotoxicosis
 - (Due to direct toxic effect of lithium on the thyroid gland)

- Cardiac Effects:
 - ECG changes(common) T-wave flattening/inversion and appearance of U waves
 - Very rare tachy/brady arrhythmias
 - e.g. AV conduction block Torsade de pointes

• Skin Effects:

- Allergic reactions -dermatitis, folliculitis, and vasculitis
- Acne- worsening and new onset
- Psoriasis worsening as well as new
- Alopecia

Li and Pregnancy

- 1st Trimester:Cardiovascular anomalies of the newborn, especially Ebstein's malformation
- 3rd Trimester: Neonatal goiter, CNS depression, hypotonia ("floppy baby" syndrome)

DRUG INTERACTIONS

- Diuretics(esp. thiazides)
- NSAIDs
- ACEIs, ARBs



• Xanthines (theophylline,caffeine)

reduce Li concentration

Li TOXICITY

• Levels > 1.5 mEq/L are toxic

<u>MILD</u>

Nausea Diarrhoea Blurred vision, Polyuria Fine tremor Muscle weakness Drowsiness

MODERATE Confusion/stupor, Fasciculation Increased reflexes Myoclonic jerks, Choreoathetosis



SEVERE

Coma Convulsions Irreversible CNS damage Cardiac toxicity (Heart block, low BP) Renal failure